Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
NASDAQ:EVAX
Price:
3.9092 USD
-0.02%
Market Closed
Updated:
May 7, 2024
Evaxion Biotech A/S
Operating Income
|
Evaxion Biotech A/S
Operating Income Peer Comparison
Comparables:
GMAB
ZEAL
ASND
B
BAVA
BIOPOR
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Operating Income
-$22.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Operating Income
kr5.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
31%
|
CAGR 10-Years
54%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Operating Income
-kr561.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-12%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Operating Income
-€361m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Operating Income
kr2.1B
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
51%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Operating Income
-kr60.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-12%
|
See Also
What is Evaxion Biotech A/S's Operating Income?
Operating Income
-22.2m
USD
-22.2m
USD
Based on the financial report for Dec 31, 2023, Evaxion Biotech A/S's Operating Income amounts to -22.2m USD.
What is Evaxion Biotech A/S's Operating Income growth rate?
Operating Income CAGR 5Y
-32%
-32%
Over the last year, the Operating Income growth was 12%. The average annual Operating Income growth rates for Evaxion Biotech A/S have been -10% over the past three years , -32% over the past five years .
You don't have any saved screeners yet
